Status:
COMPLETED
Efficacy and Safety of Ostenil® Plus in the Treatment of Coxarthrosis
Lead Sponsor:
TRB Chemedica AG
Conditions:
Coxarthrosis
Eligibility:
All Genders
18-99 years
Brief Summary
PMCF study to observe the Routine application of Ostenil® Plus in the Treatment of pain and restricted mobility in degenerative and traumatic changes of the Hip Joint.
Eligibility Criteria
Inclusion
- Subjects ≥ 18 years of age and in good general health condition
- Signed informed consent
- Existing Ostenil® Plus recommendation for the treatment of coxarthrosis
Exclusion
- Known hypersensitivity to one of the OSTENIL® PLUS components
- Known pregnancy or lactating females
- Previous/concomitant participation in clinical investigation within the last 3 months prior to study inclusion
- Subjects not capable of contracting and of understanding the nature, risks, significance and implications of the clinical investigation and unable to form a rational intention in the light of these facts
- Subjects unable to understand informed consent or having a high probability of non compliance to the study procedures and / or non completion of the study according to investigator's judgement (e.g. illiteracy, insufficient knowledge of local language)
Key Trial Info
Start Date :
February 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 14 2025
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT03809962
Start Date
February 15 2019
End Date
May 14 2025
Last Update
June 5 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Orthopädische Praxis Rahlstedt
Hamburg, Hamburg, Germany, 22143
2
Gemeinschaftspraxis für Orthopädie und Unfallchirurgie
Bad Oldesloe, Schleswig-Holstein, Germany, 23843
3
Orthopraxis Kiel
Gettorf, Schleswig-Holstein, Germany, 24214
4
Zentrum für Medizin des Bewegungsapparates
Heide, Schleswig-Holstein, Germany, 25746